-
In 2023, these 20 blockbuster new drugs are expected to be approved in China
Time of Update: 2022-12-30
Since 2022, the international situation is severe and complex, the epidemic continues to progress, China's pharmaceutical industry has inevitably been affected, up to now, the State Medical Products
-
Issue 17/2017 - Global Chemicals Quick Review
Time of Update: 2022-11-11
Uganda moves forward with new refinery projectsUganda's energy ministry said Uganda would continue to develop large oil fields and had agreed to the terms of a core project to invest $2.
-
Local pharmaceutical companies are innovating, and the competition for talents has been surging
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; In recent years, with the promotion of the new medical reform policy, the domestic pharmaceutical industry has gradually upgraded from generic drugs to innovative drugs, and local pharmaceutical companies have accelerated the pace of innovation and transformation.
-
During the year, more than 1,000 listed companies set off a wave of buybacks, and pharmaceutical companies became "frequent customers
Time of Update: 2022-10-25
In terms of the number of repurchases, WuXi Biologics has been active in repurchases, with a total of eight repurchases in the past month, with a total capital contribution of nearly HK$1 billion and more than 20 million shares repurchased (data as of the market close on October 14).
-
Pharmaceutical equipment welcomes a big plus and will open a new journey for the industry
Time of Update: 2022-06-14
After years of development, my country's pharmaceutical equipment products are becoming increasingly diverse, with continuous specifications, and the market size is showing an increasing trend, which has basically been able to meet the production needs of domestic pharmaceutical companies.
-
A variety of parenteral nutrition therapy drugs have been approved one after another, and the market of 10 billion yuan will be in waves
Time of Update: 2022-05-19
Coincidentally, Kelun Pharmaceutical also issued two consecutive announcements recently, stating that the company's medium and long chain fat emulsion/amino acid (16)/glucose (36%) injection and medium and long chain fat emulsion/amino acid (16)/glucose (30%) %) injection was approved on the same day as the imitation class 3, which is regarded as over-evaluation.
-
In the future, medical representatives will continue to be under pressure, where is the way out
Time of Update: 2022-01-08
So, in the context of the continuous deepening of medical reform and the normalization of centralized procurement, how should these medical representatives find new ways in the future?
-
The CDK family is in full bloom. Dozens of domestic pharmaceutical companies have entered the track
Time of Update: 2021-09-20
Today, Ibrance has grown into a blockbuster drug with annual sales of more than US$5 billion, followed by 3 CDK4/6 inhibitors in China; , Jiangsu Hengrui’s SHR-6390 has also entered the NDA stage.
-
The US version of "medical insurance catalog negotiation" is here
Time of Update: 2021-09-19
"The NHS supports the passage of legislation and allows the federal government to negotiate annually to reduce the prices of the most expensive prescription drugs and pass the costs on to private insurance companies .
-
How difficult is it to get a generic drug for Seretide on the market
Time of Update: 2021-04-23
Recently, Hengrui issued an announcement stating that, in accordance with the latest policy of the State Food and Drug Administration on drug review and approval, combined with the company's actual situation, it has submitted to the State Food and Drug Administration an application for withdrawal of salmeterol ticasone powder inhalation drug registration.
-
Greenlee Pharmaceuticals and AstraZeneta are once again strategically working together to actively advance the cardiovascular and oncology sectors
Time of Update: 2021-01-04
On December 28, 2020, Greenleaf Pharmaceutical Group and AstraZeneca signed a Memorandum of Strategic Cooperation, which will actively explore in-depth cooperation in the field of cardiovascular and oncology, focusing on green leaf pharmaceutical's natural drug hemolipid congen ®capsulates, in the field of oncology, innovative agent lipotin® and the anti-tumor biopharmaceutical beva bead monoantigen (LY01008) developed by Shandong Boan Biotechnology Co., Ltd., a subsidiary of Greenleaf Pharmaceuticals.
-
A batch of drugs has been suspended for recall: acetaminophen tablets
Time of Update: 2020-12-12
, the drug regulatory department has asked the relevant units to take risk prevention and control measures to investigate and punish non-conforming products in accordance with relevant laws and regulations.
-
Within two months, a well-known domestic pharmaceutical companies to cooperate with three commercial giants
Time of Update: 2020-11-20
signing ceremony, Shanghai Pharmaceutical Holdings and North China Pharmaceuticals related business leaders respectively on the development of their respective enterprises, industrial layout, marketing structure, social responsibility and cooperation prospects for the introduction and communication.
-
Yuandong Bio "Grom bromine ammonium injection" is about to be approved for the second time
Time of Update: 2020-10-21
Compared with Athosin, ammonium Glon bromide inhibits salivary secretion for a strong and long-lasting effect, with low cardiovascular adverse reactions, and the drug lipid membrane has poor passability and is not easy to pass through the blood-brain barrier, thus affecting the central nervous system less.
-
Chinese and foreign pharmaceutical companies have joined forces to become the trend
Time of Update: 2020-09-06
recently, on August 17th, Bayer announced a strategic partnership with Huali Pharmaceuticals, an innovative drug research and development company, to reach a commercial cooperation agreement in China on the new diabetes treatment drug dorzagliatin.
